Demo Mode — Sample Data Only

Arcturus Capital Partners IV

DEMO
Back to Portfolio

Nexagen Technologies

Technology
$50M – $200M
68
healthy
EBITDA Margin15.0%
DSO (T3M)40 days
CCC (T3M)9 days
Net Debt / EBITDA1.6x
WC Opportunity

EBITDA Margin Trend

Revenue Trend

Seasonality Analysis

Revenue CV0.0%
Classificationstable
Primary WC MethodT3M

Revenue shows stable patterns. Trailing 3-month (T3M) metrics provide the most current operational picture.

Growth Context

Revenue Growth (YoY)13.5%

Revenue growth is within normal range. No growth-related adjustments applied to health scoring.